DaVita (NYSE:DVA - Get Free Report) updated its FY 2025 earnings guidance on Monday. The company provided earnings per share guidance of 10.200-11.300 for the period, compared to the consensus earnings per share estimate of 11.030. The company issued revenue guidance of -.
Wall Street Analysts Forecast Growth
A number of research analysts have commented on the stock. Barclays raised their price target on shares of DaVita from $164.00 to $169.00 and gave the stock an "equal weight" rating in a research note on Tuesday, February 18th. StockNews.com raised shares of DaVita from a "hold" rating to a "buy" rating in a research note on Friday, April 25th. Cowen reaffirmed a "hold" rating on shares of DaVita in a research report on Tuesday, February 18th. Finally, Sanford C. Bernstein set a $184.00 target price on shares of DaVita in a report on Friday, February 21st. One analyst has rated the stock with a sell rating, four have issued a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, DaVita currently has an average rating of "Hold" and a consensus price target of $166.33.
Read Our Latest Analysis on DVA
DaVita Price Performance
Shares of NYSE DVA traded up $0.53 during trading hours on Monday, hitting $144.29. 1,271,868 shares of the stock were exchanged, compared to its average volume of 820,697. The company has a debt-to-equity ratio of 23.18, a quick ratio of 1.21 and a current ratio of 1.26. The company has a market cap of $11.09 billion, a PE ratio of 13.43, a price-to-earnings-growth ratio of 1.07 and a beta of 1.14. The company's fifty day simple moving average is $145.85 and its two-hundred day simple moving average is $153.83. DaVita has a 1-year low of $131.44 and a 1-year high of $179.60.
DaVita (NYSE:DVA - Get Free Report) last issued its earnings results on Monday, May 12th. The company reported $2.00 earnings per share for the quarter, beating analysts' consensus estimates of $1.75 by $0.25. DaVita had a net margin of 7.31% and a return on equity of 115.48%. On average, sell-side analysts predict that DaVita will post 10.76 EPS for the current year.
About DaVita
(
Get Free Report)
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider DaVita, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DaVita wasn't on the list.
While DaVita currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
